The vision of FutureFoodS is to collectively achieve environmentally-friendly, socially secure, fair and economically viable healthy and safe Food Systems (FS) for Europe. FutureFoodS gather 87 partners from 22 EU Member States, 6 Associated Countries and 1 third country. FutureFoodS includes public and private actors, policy makers, foundations, locally, sub-nationally, nationally, EU-widely. All these FutureFoodS partners are fully aligned on the vision for the Partnership and the methodology for its implementation in line with SDG17 and EU Green Deal components. This vision has been broken down into general (GO), specific (SO) and operational (OO) objectives applying across the 4 R&I areas and 4 transversal activities identified by the FutureFoods consortium in its stable draft Strategic Research and Innovation Agenda (SRIA) which constitutes the strategic backbone of the project. The four GO cover: GO1 - Functioning of FS; GO2 - System approaches; GO3 - Inclusive government; GO4 - Co-creation cases. These GO have then been translated into SO prioritised in line with the timescale and resources of the Partnership: SO1 - Change the way we eat; SO2- Change the way we process and supply food, SO3 - Change the way we connect with FSs and SO4 - Change the way we govern FS. In addition, 6 interconnected OO have been set: OO1- Pooling R&I resources and programming; OO2 - Operational FS Observatory; OO3 - Active FS knowledge Hub of FS Labs; OO4 - Functioning knowledge sharing and scaling mechanisms; OO5- Revisiting the SRIA; OO6 - Promoting, supporting, widening & gathering FS various communities. The objectives implemented in the 8 WPs of FutureFoodS will exert impact directly or indirectly in most of the destinations of Horizon Europe’s Cluster 6 2023-2024 work programme and particularly for the topic destination ‘Fair, healthy and environment-friendly FS from primary production to consumption’ echoing to the main EU and World FS policies & strategies.

Personalized medicine uses pharmacogenomics (PGX) to individualize therapy upon patients’ unique DNA profiles. With ~200,000 deaths/year in Europe due to adverse drug reactions, it has become an imperative to improve treatment. In Western Balkans (WB), individualization of therapy is done sporadically. IMGGE (Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia) is a pioneer in the PGX in WB. PharmGenHUB will strengthen IMGGE’s PGX R&I potential by exchanging knowledge between IMGGE and EU partnering institutions: University of Patras, Greece (UPAT), University of Ljubljana, Slovenia (UL), University of Trieste, Italy (UNITS). Through collaboration and knowledge sharing with 3 EU partners, IMGGE will become WB central place for PGX diagnostics and R&I, education and trainings, and translation of PGX knowledge into clinically applicable digital solutions. IMGGE’s research project, high-throughput DNA sequencing of WB populations, with support of UPAT and UL, will identify WB specific drug-PGX marker pairs and enable design of electronic tool for better decision-making in clinical practice, electronic PGX assistant for WB (ePGA-WB). iPSC model for validation of novel PGX markers relevant for Europe will be introduced at IMGGE with support of UNITS. IMGGE will renew, reinforce and establish new connections through networking with WB institutions. Project will be realized through short-term visits of IMGGE staff to EU partner institutions, staff exchanges, on-site trainings, experimental laboratory work. Outreach activities will include PGX days, WB conference and joint summer schools. To strengthen research management capacities and administrative skills of IMGGE staff, a research management unit will be established with assistance from UPAT. As focal point of PGX translational research, IMGGE will impact on WB health-care cost benefits and facilitate WB integration to EU-PGX research area through R&I activities and digitalization.

The INTERfaces program will train 14 ESRs within an EID network jointly designed by European academic and industry partners in innovative research projects dedicated to developing clean bioprocesses for the production of chemicals. The assembly of biocatalysts to reaction sequences allows avoiding steps for isolation and purification of intermediates and thus a significant improvement of the environmental footprint of catalytic processes. The main goal of INTERfaces is the extension of this concept towards multi-step biocatalytic reactions in immobilized form. These “Heterogeneous Biocatalytic Reaction Cascades” will greatly facilitate re-use of the catalysts and further simplify downstream-processing. INTERfaces combines material science and protein engineering to design tailored enzymes and (bio-based) materials that will complement each other to obtain optimized heterogeneous biocatalysts. These tools will be applied to solve synthetic challenges in the use of two biobased monomers as starting materials to synthesize products for application fields like antioxidants and biopolymers. Process optimization and up-scale in industry will reveal key factors for synthetic utilization of the biocatalysts. INTERfaces emphasizes particularly the engineering of the designed cascades in solid phase. This includes the design of reactors, use of computational modeling tools, application of the right operational modes, and reaction medium needed for desired space-time-yields and product titers. Commercial relevant processes will be up-scaled together with industry for technical implementation. 13 Non-academic partners ranging from high-tech SMEs to large producing companies and 9 academic institutions offer an intersectoral and interdisciplinary environment to provide 14 Ph.D. candidates with outstanding employability profiles for the European Biotech Sector. Dedicated workshops and well-balanced supervisory team aim at increasing the gender diversity in biotech research.

The TRIM-NET innovative training programme will provide Early-Stage Researchers with the skills to identify novel therapeutic targets and develop the strategies to validate them in preclinical studies. Integrating complementary expertise and multidisciplinary approaches TRIM-NET aims to address this goal, focussing on the Tripartite motif (TRIM) family of Ubiquitin E3 ligases, which plays an important role in many physiological processes. The importance of the role of TRIM proteins in these processes is underpinned by their recognised involvement in many disease processes such as cancer, neurodegeneration and rare genetic diseases. As such, they are excellent targets for therapeutic manipulation. The TRIM-NET consortium created a critical mass with complementary and interdisciplinary expertise, from Life Science to Chemistry, around this family of proteins to identify and exploit common targeting strategies for translational applications. The consortium is designed to train a cohort of researchers in skills and expertise essential for biomedical research in the era of personalised medicine, focussing on determining how: i) TRIM proteins contribute to disease; ii) to develop strategies to modulate TRIM proteins activity; iii) to design high throughput screening assays for drug discovery. The training programme comprises 7 highly integrated work packages: 4 scientific and 3 dedicated to training, dissemination and management. The proposal consists of 12 individual research projects that will form the basis of the research training aspects for the ESR recruited to the programme. As the scientific work packages are highly integrated, recruited ESRs will avail of techniques and training opportunities, including secondments, across the work packages. Through a unique international partnership between academic and non-academic partners the TRIM-NET training programme will provide ESRs with skills that are essential for future biomedical research in industry and academia.